1. Home
  2. UNCY vs LNSR Comparison

UNCY vs LNSR Comparison

Compare UNCY & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$6.06

Market Cap

121.9M

Sector

Health Care

ML Signal

HOLD

Logo LENSAR Inc.

LNSR

LENSAR Inc.

HOLD

Current Price

$10.20

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UNCY
LNSR
Founded
2016
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Electronics
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
121.9M
142.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
UNCY
LNSR
Price
$6.06
$10.20
Analyst Decision
Strong Buy
Hold
Analyst Count
4
1
Target Price
$44.50
$15.00
AVG Volume (30 Days)
451.4K
75.5K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$59,141,000.00
Revenue This Year
N/A
$30.80
Revenue Next Year
$19,392.60
$33.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.02
52 Week Low
$3.71
$7.13
52 Week High
$11.00
$17.31

Technical Indicators

Market Signals
Indicator
UNCY
LNSR
Relative Strength Index (RSI) 61.73 43.43
Support Level $5.96 $9.56
Resistance Level $6.70 $10.48
Average True Range (ATR) 0.46 0.37
MACD 0.06 0.07
Stochastic Oscillator 63.68 74.71

Price Performance

Historical Comparison
UNCY
LNSR

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

About LNSR LENSAR Inc.

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

Share on Social Networks: